Genting New Dawn announced that its wholly owned subsidiary EverSea Medicines will acquire 100% equity of Haisen Biopharmaceuticals (Singapore) by 2026, at a total consideration of $250 million, paid in three installments. This transaction will help the company expand its market presence and diversify its business in the Asia-Pacific region.